Gossamer Bio holds special stockholder meeting
GOSS•Gossamer Bio shareholders approved a proposal authorizing common stock issuance exceeding 20% of shares outstanding before the initial closing under an August 20, 2026, purchase agreement.
1. Share issuance approved
At an October 27, 2026, special meeting, Gossamer Bio shareholders approved potential common stock issuance exceeding 20% of shares outstanding immediately before the initial closing under the August 20, 2026, Purchase Agreement. The authorization includes shares issuable through Pre-Funded Warrants, FDA Approval Warrants and conversion of Series A-1, A-2 and A-3 Preferred Stock; an adjournment proposal was not put to a vote.
